In 2019 the biosimilars market became a teenager, having been "born" in April 2006, following the European Medicines Agency’s (EMA's) approval of its first biosimilar -Omnitrope, Sandoz’s growth hormone biosimilar.
In certain regions such as Europe, biosimilars have begun to deliver on their promise of making high-quality, safe and effective...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?